March 23, 2015 +44 (0)20 7025 7911 [email protected]


Complement plays an important role in many inflammatory and autoimmune disorders offering a very wide choice of target indications. Outstanding preclinical results have been obtained in many areas including haematology, peripheral and central neurological disorders, nephrology, cardiovascular and infectious diseases. In selecting its initial disease targets VIP has concentrated on rare disabling diseases with limited or no effective treatment options. VIP has identified targets in five major disease areas for potential clinical development:


Complement activation is known to be critical in a number of autoimmune haematological conditions including paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS) and antiphospholipid syndrome (APS). It has now been shown in clinical practice that C5a inhibition has a dramatic beneficial effect in a number of these conditions and provides an effective alternative to conventional therapy including repeated plasma exchanges.

Coversin has been shown to be as effective as eculizumab ( Soliris ® ) in blood from PNH patients at a molar equivalent dose. (CLICK HERE to view the Coversin paper at the British Society of Haematology, Birmingham UK, April 2014) VIP is planning multicentre PII/III trials in PNH beginning Q1 2015. Other thrombotic micro-angiopathies such as aHUS and TTP are currently being considered as follow-on targets.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.